Moreover, iRGD modification greatly improves tumor accumulation and release while reducing uptake by normal tissues, thereby increasing safety.[55] Taken together, iRGD NPs@si‐SOX9/CL outperforms traditional therapeutic strategies in targeting, efficacy, and immune activation, offering a novel multi‐modal precision therapy for GC. The gene discussed is SOX9; the disease is gastric cancer.